Home

KIMBERLY MANHARD

CIK 1202094 · EVP, Drug Development · last filed 2026-06-04

KIMBERLY MANHARD is an EVP, Drug Development who has filed 86 SEC Form 4 insider transactions across 4 companies since 2008. The most recent filing, for INBX, was dated Jun 4, 2026. Across all open-market trades the lifetime net is −$6.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions. 6 SEC filings were submitted jointly with Inhibrx, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.22M

Companies

4

Total Filings

86

Lifetime Open-Market Net

-$6.42M

Filer Profile

Reported Address
C/O HERON THERAPEUTICS, INC
4242 CAMPUS POINT COURT, SUITE 200
SAN DIEGO, CA 92121
Related Filers
Inhibrx, Inc. — 6 joint filings, latest 2024-05-30
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
INBX Director 10,000 $121.17 $1.21M $139.8K 7 2026-06-04
Inhibrx, Inc. (INBXV) Delisted Director — — — $0 1 2024-05-30
HRTX EVP, Drug Development 28,330 $0.34 $9.7K -$2.65M 33 2023-04-17
Ardea Biosciences, Inc./DE (RDEA) Delisted SVP, Regulatory & Dev Ops 0 — — -$3.90M 43 2012-06-20

Recent Filings

86 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-04 INBX Grant (A) — $0 EDGAR
2025-05-29 INBX Grant (A) — $0 EDGAR
2024-08-30 INBX Buy (P) +10,000 $139.8K EDGAR
2024-05-30 — Grant (A) — $0
2024-05-30 Inhibrx, Inc. (INBXV) Delisted Disp (D) — $0 EDGAR
2023-05-30 INBX Grant (A) — $0 EDGAR
2023-04-17 HRTX Mixed +4,397 -$4.1K EDGAR
2023-01-20 HRTX Grant (A) — $0 EDGAR
2023-01-17 HRTX Mixed +5,457 -$962 EDGAR
2022-10-17 HRTX Mixed +3,802 -$7.6K EDGAR
Showing 1–10 of 86
Page 1 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.